Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp

被引:14
|
作者
Murali, Mahadevamurthy [1 ]
Gowtham, Hittanahallikoppal Gajendramurthy [2 ]
Ansari, Mohammad Azam [3 ]
Alomary, Mohammad N. [4 ]
Alghamdi, Saad [5 ]
Almehmadi, Mazen [6 ]
Singh, Sudarshana Brijesh [2 ]
Shilpa, Natarajamurthy [7 ]
Aiyaz, Mohammed [2 ]
Kalegowda, Nataraj [1 ]
Ledesma, Ana E. [8 ]
Amruthesh, Kestur Nagaraj [1 ]
机构
[1] Univ Mysore, Dept Studies Bot, Appl Plant Pathol Lab, Mysuru 570006, Karnataka, India
[2] Univ Mysore, Dept Studies Biotechnol, Mysuru 570006, Karnataka, India
[3] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat IRMC, Dept Epidem Dis Res, Dammam 31441, Saudi Arabia
[4] King Abdulaziz City Sci & Technol KACST, Natl Ctr Biotechnol, POB 6086, Riyadh 11442, Saudi Arabia
[5] Umm Al Qura Univ, Fac Appl Med Sci, Lab Med Dept, Mecca 21955, Saudi Arabia
[6] Taif Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Taif 21944, Saudi Arabia
[7] Univ Mysore, Dept Studies Microbiol, Mysuru 570006, Karnataka, India
[8] Univ Nacl Santiago del Estero, Ctr Invest Biofis Aplicada & Alimentos, FCEyT, CIBAAL UNSE CONICET, RN 9,Km 1125, RA-4206 Santiago Del Estero, Argentina
关键词
Anti-COVID-19; drugs; anti-HIV compounds; coronaviruses; molecular docking; RNA-dependent RNA polymerase; hypericin; STRUCTURAL BASIS; DOCKING;
D O I
10.2174/1381612828666220428120939
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Coronavirus disease 2019 (COVID-19) has caused a global pandemic with a high mortality and morbidity rate worldwide. The COVID-19 vaccines that are currently in development or already approved are expected to provide at least some protection against the emerging variants of the virus, but the mutations may reduce the efficacy of the existing vaccines. Purified phytochemicals from medicinal plants provide a helpful framework for discovering new therapeutic leads as they have long been employed in traditional medicine to treat many disorders. Objective: The objectives of the study are to exploit the anti-HIV bioactive compounds against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through molecular docking studies and to evaluate the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of potential compounds. Methods: Molecular docking was performed to study the interaction of ligands with the target sites of RdRp protein (PDB: 6M71) using AutoDock Vina. The ADMET properties of potential compounds were predicted using the pkCSM platform. Results: A total of 151 phytochemicals derived from the medicinal plants with recognized antiviral activity and 18 anti-HIV drugs were virtually screened against COVID-19 viral RdRp to identify putative inhibitors that facilitate the development of potential anti-COVID-19 drug candidates. The computational studies identified 34 compounds and three drugs inhibiting viral RdRp with binding energies ranging from -10.2 to -8.5 kcal/mol. Among them, five compounds, namely Michellamine B, Quercetin 3-O-(2",6"-digalloyl)-beta-D-galactopyranoside, Corilagin, Hypericin, and 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose residues, bound efficiently with the binding site of RdRp. Besides, Lopinavir, Maraviroc, and Remdesivir drugs also inhibited SARS-CoV-2 polymerase. In addition, the ADMET properties of top potential compounds were also predicted in comparison to the drugs. Conclusion: The present study suggested that these potential drug candidates can be further subjected to in vitro and in vivo studies that may help develop effective anti-COVID-19 drugs.
引用
收藏
页码:969 / 980
页数:12
相关论文
共 50 条
  • [31] Plant-Based Phytochemical Screening by Targeting Main Protease of SARS-CoV-2 to Design Effective Potent Inhibitors
    Mahmud, Shafi
    Biswas, Suvro
    Paul, Gobindo Kumar
    Mita, Mohasana Akter
    Promi, Maria Meha
    Afrose, Shamima
    Hasan, Md. Robiul
    Zaman, Shahriar
    Uddin, Md. Salah
    Dhama, Kuldeep
    Emran, Talha Bin
    Saleh, Md. Abu
    Simal-Gandara, Jesus
    BIOLOGY-BASEL, 2021, 10 (07):
  • [32] Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2
    Bess, Adam
    Berglind, Frej
    Mukhopadhyay, Supratik
    Brylinski, Michal
    Alvin, Chris
    Fattah, Fanan
    Wasan, Kishor M.
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [33] A guide to COVID-19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS-CoV-2 infection
    Brady, Drugan K.
    Gurijala, Aashi R.
    Huang, Liyu
    Hussain, Ali A.
    Lingan, Audrey L.
    Pembridge, Olivia G.
    Ratangee, Brina A.
    Sealy, Tristan T.
    Vallone, Kyle T.
    Clements, Thomas P.
    FEBS JOURNAL, 2024, 291 (08) : 1632 - 1662
  • [34] SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection
    Smolders, Elise J.
    Brake, Lindsey Hm Te
    Burger, David M.
    ANTIVIRAL THERAPY, 2020, 25 (07) : 345 - 347
  • [35] Neurological Manifestation of SARS-CoV-2 Induced Inflammation and Possible Therapeutic Strategies Against COVID-19
    Dipak Kumar
    Sadaf Jahan
    Andleeb Khan
    Arif Jamal Siddiqui
    Neeru Singh Redhu
    Johra Wahajuddin
    Saeed Khan
    Bader Banwas
    Mohammed Alshehri
    Molecular Neurobiology, 2021, 58 : 3417 - 3434
  • [36] Neurological Manifestation of SARS-CoV-2 Induced Inflammation and Possible Therapeutic Strategies Against COVID-19
    Kumar, Dipak
    Jahan, Sadaf
    Khan, Andleeb
    Siddiqui, Arif Jamal
    Redhu, Neeru Singh
    Wahajuddin
    Khan, Johra
    Banwas, Saeed
    Alshehri, Bader
    Alaidarous, Mohammed
    MOLECULAR NEUROBIOLOGY, 2021, 58 (07) : 3417 - 3434
  • [37] Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
    Norma A. Valdez-Cruz
    Enrique García-Hernández
    Clara Espitia
    Laura Cobos-Marín
    Claudia Altamirano
    Carlos G. Bando-Campos
    Luis F. Cofas-Vargas
    Enrique W. Coronado-Aceves
    Ricardo A. González-Hernández
    Pablo Hernández-Peralta
    Daniel Juárez-López
    Paola A. Ortega-Portilla
    Sara Restrepo-Pineda
    Patricio Zelada-Cordero
    Mauricio A. Trujillo-Roldán
    Microbial Cell Factories, 20
  • [38] Microsecond MD Simulation and Multiple-Conformation Virtual Screening to Identify Potential Anti-COVID-19 Inhibitors Against SARS-CoV-2 Main Protease
    Selvaraj, Chandrabose
    Panwar, Umesh
    Dinesh, Dhurvas Chandrasekaran
    Boura, Evzen
    Singh, Poonam
    Dubey, Vikash Kumar
    Singh, Sanjeev Kumar
    FRONTIERS IN CHEMISTRY, 2021, 8
  • [39] Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
    Valdez-Cruz, Norma A.
    Garcia-Hernandez, Enrique
    Espitia, Clara
    Cobos-Marin, Laura
    Altamirano, Claudia
    Bando-Campos, Carlos G.
    Cofas-Vargas, Luis F.
    Coronado-Aceves, Enrique W.
    Gonzalez-Hernandez, Ricardo A.
    Hernandez-Peralta, Pablo
    Juarez-Lopez, Daniel
    Ortega-Portilla, Paola A.
    Restrepo-Pineda, Sara
    Zelada-Cordero, Patricio
    Trujillo-Roldan, Mauricio A.
    MICROBIAL CELL FACTORIES, 2021, 20 (01)
  • [40] SMILES-based QSAR virtual screening to identify potential therapeutics for COVID-19 by targeting 3CLpro and RdRp viral proteins
    Bazzi-Allahri, Faezeh
    Shiri, Fereshteh
    Ahmadi, Shahin
    Toropova, Alla P.
    Toropov, Andrey A.
    BMC CHEMISTRY, 2024, 18 (01)